The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVRP.L Share News (VRP)

  • There is currently no data for VRP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS SUMMARY: Spirent Up After Lifting Profit Guidance

Mon, 13th Jan 2020 10:34

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.

----------

FTSE 100 - WINNERS

----------

Taylor Wimpey, up 2.8%. Peel Hunt raised the housebuilder to Add from Hold.

----------

Hikma Pharmaceuticals, up 2.1%. The drugmaker said it has signed an exclusive licensing and distribution agreement with Italian pharma firm Chiesi Farmaceutici. The agreement provides Hikma with exclusive rights to commercialise 11 of Chiesi's products in Egypt, including currently marketed and pipeline products. Hikma noted this agreement builds on the existing partnership between the pair in Morocco.

----------

Halma, up 2.0%. Goldman Sachs raised the smoke detector maker to Buy from Neutral.

----------

Centrica, up 1.8%. UBS raised the British Gas parent to Buy from Neutral.

----------

FTSE 100 - LOSERS

----------

St James's Place, down 1.0%. Credit Suisse downgraded the wealth manager to Underperform from Neutral.

----------

FTSE 250 - WINNERS

----------

Spirent Communications, up 16%. The telecommunications network testing firm said it was able to continue its good momentum into the fourth quarter of 2019 and expects full-year profit to exceed market expectations. Spirent said it was able to secure a number of "important" contract wins in the final three months of 2019, resulting in 2019 total group revenue rising by 5.5% versus the year before to USD503 million. The company also expects its adjusted operating profit to be between USD91 million and USD93 million - which would represent a rise of between 18% and 21% on the USD77.1 million reported in 2018. "Over the medium term we expect to continue to deliver mid-single digit revenue growth with a focus on increasing recurring revenue streams to enhance the group's visibility and effective investment in our technical platforms to drive ongoing performance," Chief Executive Eric Updyke said.

----------

Pennon Group, up 7.5%. The Daily Telegraph reported that the water company's Viridor waste management arm is set to be put up for sale. Citing "City sources", the newspaper said Pennon rejected a bid from US private equity fund KKR early in 2019 that was an attempt to jump-start the sale process for Viridor. Now, banks Morgan Stanley and Barclays have been appointed to run the process at a valuation for Viridor of GBP4 billion, the newspaper said.

----------

Savills, up 5.6%. The estate agent said its annual performance will be at the upper end of expectations due to an "excellent" performance in the UK, significant growth in the US and a strong performance from the Savills Investment Management arm. Savills said despite challenges such as Brexit, and political unrest in Hong Kong contributing to lower volumes of activity, "the strength of Savills positions in both markets contributed to a resilient performance through increased market share". Savills Investment Management also performed ahead of expectations, benefiting from performance fees on "certain products". Looking to the year ahead, Savills noted global investor demand for secure income, restricted supply and expectations of continued low interest rates suggests that the medium and long term dynamics of the UK real estate market should remain largely positive.

----------

Avast, up 3.5%. JPMorgan upgraded the antivirus software maker to Overweight from Neutral.

----------

FTSE 250 - LOSERS

----------

Just Group, down 2.6%. Credit Suisse cut the retirement financial products provider to Underperform from Neutral.

----------

Mitchells & Butlers, down 2.2%. JPMorgan downgraded the pub and restaurant operator to Neutral from Overweight.

----------

OTHER MAIN MARKET AND AIM - WINNERS

----------

Verona Pharma, up 53%. The pharmaceutical company said its Phase 2b clinical trial of nebulized Ensifentrine met its primary endpoint. The four-week Phase 2b trial of the drug in moderate to severe chronic obstructive pulmonary disease patients improved lung function at week four of the treatment. In the trial, the drug was administered twice daily in combination with tiotropium, a treatment used in the management of chronic obstructive pulmonary disease and asthma.

----------

OTHER MAIN MARKET AND AIM - LOSERS

----------

City Pub, down 9.1%. The pub operator warned profit will miss market expectations due to "subdued" trading over the key Christmas period. In its financial year ended December 29, the southern England and Wales-focused pub owner said it performed well, with revenue rising 31% to GBP59.8 million. Like-for-like sales were up 1.7%, and City Pub Group said it is pleased with this performance. However, a number of one-off factors in the last quarter of its year held back fourth-quarter performance. As a result, adjusted earnings before interest, tax, depreciation, and amortisation for the year is now expected to be slightly below market expectations, between GBP9.1 million and GBP9.2 million. This would still be an approximate 15% rise year-on-year. City Pub also said the 2018 festive season was a very strong one, providing a tough comparable for the recently ended season.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
7 Mar 2014 09:39

Friday broker round-up UPDATE

AGA Rangemaster: N+1 Singer ups target price from 175p to 192p and maintains a buy recommendation. Aggreko: JP Morgan lowers target price from 1542p to 1536p and maintains a neutral rating. Goldman Sachs increases target price from 1876p to 1950p and keeps a buy recommendation. Numis upgrades to re

Read more
6 Mar 2014 18:02

Verona Pharma Looks To Raise Up To GBP14 Million In Share Placing

LONDON (Alliance News) - Verona Pharma PLC Thursday said it intends to raise up to GBP14 million before expenses in a share placing, subscription, and open offer, which it said it will use to fund further development of its RPL554 drug. The drug development company focuses on medicines to t

Read more
11 Nov 2013 08:50

Monday broker round-up UPDATE

Associated British Foods: Barclays downgrades to equal-weight with a target price of 2100p. Bovis Homes Group: Deutsche Bank moves target price from 1001p to 1008p maintaining a buy recommendation. British Land: Deutsche Bank downgrades to sell with a target price of 520p. British Sky Broadcastin

Read more
25 Oct 2013 08:35

Verona Pharma Says RPL554 Drug Trial Positive

Read more
30 Sep 2013 12:47

Verona Pharma Widens Losses As Treatment Development Continues

Read more
5 Sep 2013 09:37

Verona Pharma Appoints Chroma CEO Bungay As New Part-Time CFO

Read more
5 Sep 2013 08:15

Verona Pharma replaces CFO Lowe with Bungay

Verona Pharma on Thursday said Chief Financial Officer (CFO) Danny Lowe would be replaced by Richard Bungay with immediate effect. Bungay will work part-time at the respiratory treatments specialist at first and Lowe will work with him for an interim period to make sure there is a smooth handover.

Read more
23 Jul 2013 16:21

SABMilller Chairman sells over 11m pounds in shares

Graham Mackay, the Chairman of SABMiller who is currently on a medical leave of absence due to a brain tumour, has sold over 11m pounds-worth of shares in the company. Mackay sold a total of 350,000 shares between July 16-18th through three separate transactions, the firm revealed on Tuesday. He so

Read more
26 Apr 2013 15:09

Advanced Oncotherapy CEO makes triple purchase

The Chief Executive of Advanced Oncotherapy, a provider of new technology for innovative and patient-focused cancer treatments, has this week purchased three lots of shares in the group, taking his stake to just under 69.4m shares. On Thursday Sinclair purchased one round of 8.075m shares at 1.59p

Read more
10 Apr 2013 16:27

AZ Electronic Materials directors try to minimize damage

John Whybrow, the Chairman of AZ Electronic Materials, which on Tuesday tanked after it issued a warning on full year revenue, has shown his faith in the chemicals company by enlarging his shareholding. Whybrow acquired 40,000 shares at 254p each for a total trade value of £101,600, taking his sta

Read more
4 Sep 2012 08:58

Small caps round-up: Verona, Image Scan, Avia

Respiratory diseases specialist Verona Pharma has hailed a positive outcome of a clinical trial of its lead drug candidate, the snappily-named RPL554. The data showed that a single dose of RPL554 in spray form administered to patients with chronic obstructive pulmonary disease (COPD) produced a ra

Read more
28 Aug 2012 14:43

Small caps round-up: Transense Tech, Hightex, Verona Pharma

Transense Technologies, which provides sensor systems for the transportation and industrial markets, has reported that its trading division, Translogik, has received an initial order for its iTrack Tyre Temperature and Pressure Monitoring Systems for mining and off-the-road vehicles from its Indones

Read more
9 Jul 2012 10:25

Small caps round-up: Lighthouse, Verona Pharma, Manroy...

Shares in Lighthouse Group, the financial advice and wealth management group, plunged on Monday after the company proposed to cancel its listing on AIM. The group must receive approval from shareholders representing at least three-quarters of the company's shares for the cancellation to be approved.

Read more
26 Nov 2010 15:56

Small caps round-up: Verona Pharma, PHSC, Sterling Green

Verona Pharma, respiratory diseases treatment developer, is initiating a new higher dose trial of its lead drug, RPL554, in patients with asthma, after receiving the go-ahead from the Dutch authorities. The company also announced that it has completed proof of concept trials on delivering RPL554 vi

Read more
28 Jun 2010 07:33

Verona Pharma In Talks With Licensees For RPL554 Cough Project

LONDON (Dow Jones)--Verona Pharma PLC (VRP.LN), an AIM quoted drug discovery company, said Monday licensing discussions continue to advance with potential licensees for its RPL554 cough project and it plans three clinical trials to add value to licensing package for RPL554. MAIN FACTS: -Has

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.